UPDATE: JMP Reiterates Market Outperform On Incyte, Lowers Target To $99 Notes 'we continue to recommend shares of Incyte since ruxolitinib (rux) remains well positioned to generate $1.66B in U.S. sales in 2019'
Benzinga_Newsdesk